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Robert A. Holt1,2,3Editorial summary
The complexity of the immune system is now being
interrogated using methodologies that generate
extensive multi-dimensional data. Effective collection,
integration and interpretation of these data remain
difficult, but overcoming these important challenges
will provide new insights into immune function and
opportunities for the rational design of new immune
interventions.billions of sequences from cell populations defined byImmunogenomics is an information science
Just by counting, it becomes clear that the adaptive im-
mune system is the biggest source of human genetic
variation. Each of us carries four to five million single
nucleotide polymorphisms, and the HLA locus, the
chromosomal region most dedicated to distinguishing
self from non-self, contributes more to this total than
any other part of our genome [1]. Adding, for each of
us, the millions of uniquely randomized T- and B-cell
receptor genes that encode our immune repertoires, it
becomes apparent that at the level of DNA, immunoge-
nomic profiles are what make us most unique. This di-
versity is the source of the genetic plasticity that allows
us to thrive as individuals and as a species in an environ-
ment of persistent yet unpredictable immune challenge.
Immunogenomics, however, is not actuarial science — it
is an information science. It is a broad and diversified field
that has a long history. With advancing technology, we
continue to build on the hard work and remarkable in-
sights that established the fundamental principles and
mechanistic underpinnings of the immune system, such
as somatic recombination, clonal selection and self-
tolerance — ideas that when first described must haveCorrespondence: rholt@bcgsc.ca
1Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency,
Vancouver, British Columbia V5Z 1L3, Canada
2Department of Molecular Biology & Biochemistry, Simon Fraser University,
Burnaby, British Columbia V5A 1S6, Canada
Full list of author information is available at the end of the article
© 2015 Holt. Open Access This article is distri
License (http://creativecommons.org/licenses/
medium, provided you give appropriate credi
Commons license, and indicate if changes we
creativecommons.org/publicdomain/zero/1.0/seemed too outlandish to be real. Next-generation sequen-
cing is clearly playing a transformative role in immunoge-
nomics research, as in many areas of the life sciences,
which makes this special issue on ‘Immunogenomics in
health and disease’ very timely. Other advancing technolo-
gies are equally impactful; for example, mass cytometry
can now provide an incredibly nuanced view of the pheno-
typic diversity among immune cell subsets. Nevertheless,
working across technology platforms remains a challenge.
It is not immediately obvious how to best interrogate
hundreds of markers, derived from individuals with
unique genetic backgrounds and personalized histories
of immune exposure. Standardized laboratory work-
flows, data formats, experimental designs and statistical
methods will be necessary and, when available, will
likely place immunology among the biggest of ‘Big
Data’ enterprises in the life sciences. Here again, we
benefit from our scientific predecessors, who did not
shy from the difficult task of annotating the immune
system, and who developed an immune ontology [2, 3]
that continues to serve as a very important base in this
new era.What do we hope to discover?
Will advances in immunogenomics reinforce current
views, asymptotically filling smaller gaps in our know-
ledge with more and more prodigious data, or will
immunogenomics be transformative? One can’t know in
advance, but this discipline is now well positioned to
shed light on both new and long-standing questions. For
example, mapping the interactions between the micro-
biome and host immunity that determine commensal
versus adversarial relationships is a new challenge, and
this work has just begun in earnest. A more enduring
gap in our knowledge is the very incomplete view we
have of allelic variation within immune receptor genes, a
gap that persists due to the structural complexity of these
loci and the tendency of investigators to focus their atten-
tion on somatic rather than germline variation. An effortbuted under the terms of the Creative Commons Attribution 4.0 International
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B-cell receptor (BCR) alleles will greatly facilitate the
interpretation of antibody repertoire data, and will in turn
facilitate therapeutic antibody development, by making al-
lelic variants more readily distinguishable from somatic
hypermutations.
In the realm of cellular immunity, the determinants
of T-cell lineage specification are being elucidated, but
it remains unclear how rigidly immune cell phenotypes
are maintained. This is of key importance for T cells,
given that immunoreactivity may be either activated or
inhibited depending on the subset. Likewise, the rules
of immunodominance, whereby response to a given
antigen is a function of other antigens present, remains
opaque. Perhaps most concerning, however, is the per-
sistence of the notion that T cells are antigen specific.
It is true that in isolation a given T cell can be shown
to interact selectively with a major histocompatibility
complex (MHC) presenting one peptide but not an-
other, but the ‘one T cell–one antigen’ view articulated
in early formulations of the clonal selection theory has
been thoroughly refuted on a theoretical basis (the mil-
lions of T-cell clonotypes each of us maintains, if
monospecific, could not protect against encounters
with more than 1015 potential peptide antigens) and by
direct observation of polyspecificity in experimental
systems that allow for its detection [4].
It is inconvenient to have to consider promiscuity
when developing T-cell therapeutics, and this issue tends
to be ignored for the simple reason that we are not yet
capable of routinely measuring it. This is particularly
relevant to cancer therapy where the strategy of stimu-
lating anti-tumor immunity by blocking inhibitory im-
munological checkpoints, which hold back otherwise
reactive T cells, has shown remarkable success [5]. It is
not yet possible, however, to predict who will respond
to these therapies or the severity of the side effects be-
cause we cannot yet determine the antigen specificities
of the T cells that will be unleashed, or the conse-
quences of their cross-reactivities. Further, it tends to
be assumed that the T cells awoken by immune check-
point blockade are originally activated by tumor anti-
gens, but then become dormant. It is possible, however,
that the anti-cancer effects of tumor-resident T cells
are incidental, and represent fortuitous recognition of
tumor antigens by broadly cross-reactive T cells. This is
a speculative view, but one that needs further consider-
ation. It is consistent with the observation of viral-
specific T cells in the tumor environment, with the
intriguing (but as yet unreplicated) finding of microbial
signatures being prevalent in the neo-antigen reper-
toires of patients responding to checkpoint blockade
[6], and with established precedents of heterologous
immunity [7].Applying what we learn
Approaching immunogenomics as information science,
in pursuit of an increasingly comprehensive view of con-
nectivity within the immune system at rest and under
challenge, is likely to lead to new and better strategies
for immune intervention. For example, if T-cell promis-
cuity does prove to be an important factor underlying
the efficacy of cancer immunotherapy, then the design
of any treatment that leverages natural T-cell reactivity
should take this into account. Efforts to improve adop-
tive cell therapies may be best focused on shaping the
on-target versus off-target properties of T cells so they
can be exploited as broadly reactive agents, while re-
doubling efforts in therapeutic antibody and chimeric
antigen receptor development for therapeutic applica-
tions that require laser-like target specificity.
Another area where new insights from immunoge-
nomics might have medical relevance is in immune
regeneration. Eventually, we all face the certainty of im-
mune decline. Immunosenescence is characterized by
dwindling production of naïve lymphocytes due to
myeloid skewing and thymic degeneration, by increas-
ing representation of functionally and proliferatively
exhausted memory cells, and by deficiencies in innate
immune mechanisms [8–10]. Immune decline, already
underway as we emerge from adolescence, is an under-
lying factor in a wide spectrum of age-related disorders
and a key challenge for regenerative medicine. Will
engineered immunity be part of the solution? The der-
ivation of induced pluripotent stem cells (iPSCs) from
peripheral T cells is now routine, and the feasibility of
re-differentiating iPSCs of T-cell origin into rejuvenated
naïve effector cells that maintain antigen specificity but
show renewed proliferative capacity has now been dem-
onstrated [11, 12]. This illuminates a path to manufac-
tured, heterochthonous immunity that has the potential
to outperform substantially the current vaccine para-
digm that fails the elderly and immunocompromised. If
individual T-cell clones can be rejuvenated in this manner,
why not B cells too? Why not ensembles of lymphocytes
with defined specificities that can be rejuvenated and
released in their host as protective anti-pathogen or anti-
tumor swarms? It’s still early days, but advancing tech-
nologies and creative immunogenomic approaches are
providing an increasingly detailed view of how immun-
ity is orchestrated. With the roles and dependencies of
the various players coming into clearer focus, and the
tools on hand to manipulate them, a future of intelli-
gent immune design awaits.
Abbreviation
iPSC: induced pluripotent stem cell.
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